N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
| Title | Journal |
|---|---|
| Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. | Toxicology letters 20180701 |
| Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. | Cancer discovery 20180701 |
| Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. | Expert review of clinical pharmacology 20160101 |
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. | The New England journal of medicine 20151105 |
| Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20140101 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Novel molecular targeted therapies for refractory thyroid cancer. | Head & neck 20120501 |
| Novel molecular targets for the therapy of castration-resistant prostate cancer. | European urology 20120501 |
| Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. | Cancer discovery 20120301 |
| c-Met is a marker of pancreatic cancer stem cells and therapeutic target. | Gastroenterology 20111201 |
| Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. | Molecular cancer therapeutics 20111201 |
| Novel therapies for metastatic castrate-resistant prostate cancer. | Journal of the National Cancer Institute 20111116 |
| Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). | Drugs of today (Barcelona, Spain : 1998) 20111101 |
| VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. | Cancer research 20110715 |
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701 |
| Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110615 |
| The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. | The Journal of clinical endocrinology and metabolism 20110601 |
| XL184 (cabozantinib) for medullary thyroid carcinoma. | Expert opinion on investigational drugs 20110301 |
| Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. | Endocrine journal 20110101 |
| Novel treatment of medullary thyroid cancer. | Current opinion in endocrinology, diabetes, and obesity 20091001 |